Premium
Results of a 10‐year follow‐up study of botulinum toxin A therapy for primary axillary hyperhidrosis in Australia
Author(s) -
Rosen Robert,
Stewart Thomas
Publication year - 2018
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13727
Subject(s) - medicine , hyperhidrosis , botulinum toxin , patient satisfaction , primary treatment , surgery , physical therapy
Primary hyperhidrosis has a prevalence of 3–5% in the United States. It is a psychosocially disabling condition leading to low self‐esteem, chronic stress and depressive symptoms. Several medical and surgical treatments exist, including botulinum toxin A, which internationally, has been shown effectively and safely to treat this condition achieving high patient satisfaction. In Australia, botulinum toxin A has been available under the Medicare benefits scheme for axillary hyperhidrosis since 2013, but efficacy and treatment satisfaction had not been evaluated. We present the results of the first Australian study on efficacy and patient satisfaction with botulinum toxin A in primary axillary hyperhidrosis with evaluation of possible prognostic factors.